AUTHORS
Paresh P Kulkarni, MBBS, MD, PhD, Young Jun Shim, PhD2, Charles Sukin3, Khaled Hassan, MD4, Alok Khorana, MD5, Keith McCrae, MD6
AFFILIATIONS
1 Cleveland Clinic, CLEVELAND, Ohio, United States
2 Cleveland Clinic, CLEVELAND, Ohio, United States
3 Cleveland Clinic, CLEVELAND, Ohio, United States, Northeast Ohio Medical University, Rootstown, Ohio, United States
4 Cleveland Clinic, CLEVELAND, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, CLEVELAND, Ohio, United States, Cleveland Clinic, CLEVELAND, Ohio, United States
ABSTRACT
Introduction
Platelets are pivotal to prothrombotic states in diseases such as cancer. Cancer-associated thrombosis (CAT) is the second leading cause of mortality in cancer patients and is particularly common in patients receiving immunotherapy. Two functionally distinct platelet phenotypes exist: proaggregatory, exhibiting integrin activation but low phosphatidylserine (PS) exposure, and procoagulant, displaying high PS exposure but lacking integrin activation. In murine models of cancer, the platelet population is skewed toward the procoagulant phenotype. Although we and others have demonstrated a skewing of energy metabolism towards glycolysis and pentose phosphate pathway (PPP) in agonist-stimulated platelets, a definitive metabolic phenotyping is yet to be undertaken for procoagulant platelets. We explored platelet activation state as well as changes in metabolism that might underlie the procoagulant platelet phenotype in cancer.
Methods
Venous blood was drawn from 9 patients with non-small cell lung cancer (NSCLC), and 9 healthy controls. Washed human platelets were prepared by differential centrifugation. We performed metabolomic profiling (MetwareBio Inc.) of the isolated platelets by untargeted metabolomics. The differential levels analysis, pathway analysis, and PCA were performed using Metaboanalyst. Another fraction of washed platelets either remained unstimulated or were treated with convulxin and/or thrombin, labelled with FITC-PAC1, APC-anti-CD62P antibody and PE-Annexin V for 30 min in the dark, and then analyzed by flow cytometry. In another set of experiments, BALB/c mice carrying CT26 colon cancer cell line tumors were either treated with immune checkpoint inhibitors (anti-PD1/anti-CTLA4) (ICI) or control IgG. Non-tumor bearing mice served as controls. Retroorbital blood was collected from these mice (n=3/group) and washed platelets were isolated. Platelets either remained unstimulated or were treated with convulxin and/or thrombin, labelled with FITC-anti-CD62P antibody and PE-Annexin V, and then analyzed by flow cytometry.
Results
Unstimulated platelets from NSCLC patients exhibited higher PS exposure but similar P-selectin expression and PAC1-binding compared to healthy individuals, suggesting induction of procoagulant activity. Untargeted metabolomics revealed a significant downregulation of phosphoenolpyruvate, 3-phosphoglycerate, glutamine and arginine but upregulation of citrate and ADP in platelets from NSCLC patients compared to those from healthy controls. Pathway analysis revealed TCA cycle, and alanine, aspartate and glutamate metabolism to be the principal pathways that were altered in NSCLC among others. We also found that unstimulated platelets from tumor-bearing mice exhibited higher PS exposure but similar P-selectin expression than non-tumor bearing mice especially after ICI treatment, suggesting induction of procoagulant activity. We hypothesized that mitochondrial respiration maintains high mitochondrial membrane potential, thus steepening the electrical gradient across the inner mitochondrial membrane that in turn promotes mitochondrial calcium influx and procoagulant platelet formation. Accordingly, convulxin and thrombin induced procoagulant phenotype in healthy donor platelets was significantly reduced following pretreatment with mitochondrial OXPHOS inhibitor (oligomycin), mitochondrial calcium uptake inhibitor (Ru360) or a mitochondrial uncoupler (CCCP), but not with the PPP inhibitor (dehydroepiandrosterone). Dehydroepiandrosterone, but not oligomycin, inhibited proaggregatory responses in healthy donor platelets.
Conclusion
We show that platelets are skewed towards the procoagulant phenotype in cancer and is accentuated by ICI treatment. We unravel a metabolic switch towards the mitochondrial TCA cycle from glycolysis in these platelets using untargeted metabolomics. We also establish its relevance to a procoagulant phenotype by showing that forcing metabolic flux in platelets towards glycolysis using mitochondrial inhibitors abolishes agonist-induced procoagulant activity in healthy platelets. These findings improve our understanding of platelet activation state and underlying metabolic changes in cancer. We also demonstrate that energy metabolism pathways may reciprocally regulate proaggregatory and procoagulant platelet responses in general.
DISCLOSURES
Charles Sukin: No relevant conflicts of interest to declare.